Comparing Chemotherapy Combos for High-Risk AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a recent diagnosis of acute myeloid leukemia (AML).
- Your AML must be considered 'high risk' — for example, because of unfavorable gene changes or a history of other bone marrow diseases.
- You should not have received prior treatment for AML (except low-dose drugs to control cell counts).
- Your overall health should be good enough that you can manage daily activities (doctor will confirm).
- Your kidneys, liver, and heart must be functioning well enough to safely receive the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
This trial tests whether a new combination (DEC3-VEN) works better than two other standard treatments for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find the best initial therapy to help achieve remission.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
Hear when a new Newly Diagnosed Acute Myeloid Leukemia With High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.